JP2023098935A5 - - Google Patents

Download PDF

Info

Publication number
JP2023098935A5
JP2023098935A5 JP2023061241A JP2023061241A JP2023098935A5 JP 2023098935 A5 JP2023098935 A5 JP 2023098935A5 JP 2023061241 A JP2023061241 A JP 2023061241A JP 2023061241 A JP2023061241 A JP 2023061241A JP 2023098935 A5 JP2023098935 A5 JP 2023098935A5
Authority
JP
Japan
Prior art keywords
vaccine formulation
seq
sequence
vaccine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023061241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023098935A (ja
Filing date
Publication date
Priority claimed from JP2020520602A external-priority patent/JP7258870B2/ja
Application filed filed Critical
Publication of JP2023098935A publication Critical patent/JP2023098935A/ja
Publication of JP2023098935A5 publication Critical patent/JP2023098935A5/ja
Pending legal-status Critical Current

Links

JP2023061241A 2017-10-12 2023-04-05 歯周炎ワクチンおよび関連組成物ならびに使用方法 Pending JP2023098935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762571582P 2017-10-12 2017-10-12
US62/571,582 2017-10-12
JP2020520602A JP7258870B2 (ja) 2017-10-12 2018-10-11 歯周炎ワクチンおよび関連組成物ならびに使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020520602A Division JP7258870B2 (ja) 2017-10-12 2018-10-11 歯周炎ワクチンおよび関連組成物ならびに使用方法

Publications (2)

Publication Number Publication Date
JP2023098935A JP2023098935A (ja) 2023-07-11
JP2023098935A5 true JP2023098935A5 (enExample) 2023-11-08

Family

ID=64110091

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520602A Active JP7258870B2 (ja) 2017-10-12 2018-10-11 歯周炎ワクチンおよび関連組成物ならびに使用方法
JP2023061241A Pending JP2023098935A (ja) 2017-10-12 2023-04-05 歯周炎ワクチンおよび関連組成物ならびに使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020520602A Active JP7258870B2 (ja) 2017-10-12 2018-10-11 歯周炎ワクチンおよび関連組成物ならびに使用方法

Country Status (14)

Country Link
US (3) US10835590B2 (enExample)
EP (1) EP3694547A1 (enExample)
JP (2) JP7258870B2 (enExample)
KR (2) KR20230066660A (enExample)
CN (1) CN111225684A (enExample)
AU (1) AU2018347511A1 (enExample)
CA (1) CA3078630A1 (enExample)
EA (1) EA202090908A1 (enExample)
IL (1) IL273690A (enExample)
MA (1) MA50363A (enExample)
MX (1) MX2020003810A (enExample)
PH (1) PH12020550239A1 (enExample)
SG (1) SG11202003147XA (enExample)
WO (1) WO2019075260A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347511A1 (en) * 2017-10-12 2020-05-21 Vaxcyte, Inc. Periodontitis vaccine and related compositions and method of use
WO2025019900A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Chimeric protein vaccine
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128338A (ja) 1982-12-08 1984-07-24 Kitasato Inst:The 歯周炎予防用ワクチン及びその製法
ATE182336T1 (de) 1993-05-28 1999-08-15 Chiron Corp Peptidinhibitoren der urokinaserezeptor-aktivität
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
US6129917A (en) * 1996-03-22 2000-10-10 The University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
US6833262B1 (en) 1999-04-21 2004-12-21 University Of Georgia Research Foundation, Inc. Polypeptide having amidolytic activity for a serpin
AUPQ065299A0 (en) * 1999-05-28 1999-06-24 University Of Sydney, The A method of prophylaxis and treatment and agents useful for same
AUPQ485999A0 (en) 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
GB0411150D0 (en) 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
US9366673B2 (en) 2009-08-02 2016-06-14 Sanofi Pasteur Limited Porphyromonas gingivalis polypeptides
EP2533794A4 (en) * 2010-02-12 2014-04-23 Univ Sydney PROTEINDOMAINS AND USES THEREOF
US9040253B2 (en) 2010-04-14 2015-05-26 Sutro Biopharma, Inc. Method for enhancing recombinant protein production by cell-free protein expression system
KR102018863B1 (ko) 2012-10-12 2019-09-05 서트로 바이오파마, 인크. 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
AU2018347511A1 (en) * 2017-10-12 2020-05-21 Vaxcyte, Inc. Periodontitis vaccine and related compositions and method of use

Similar Documents

Publication Publication Date Title
JP2023098935A5 (enExample)
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
RU2010111758A (ru) Иммуногенные композиции и способы
RU2013117082A (ru) Иммуногенные композиции
JP2011506433A5 (enExample)
Schell Studies on the innate resistance of mice to infection with mousepox: II. Route of inoculation and resistance; and some observations on the inheritance of resistance
De Haan et al. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice
DK0754055T3 (da) Gruppe A-streptokok-polysaccharid-immunogen-præparater og metoder
MX2023003988A (es) Formulaciones para administración supracoroidea tales como formulaciones con formación de agregados.
ES2587962T3 (es) Conjugados de albúmina-péptido amiloide y usos de los mismos
JPH08325163A (ja) 哺乳動物用ワクチン組成物
WO2021254287A1 (zh) 新型冠状病毒的串联表位多肽疫苗及其应用
KR970703164A (ko) 헬리코박터류 감염의 치료 및 예방용 항원 제제(treatment and prevention of helicobacter infection)
CA1297003C (en) Composition and method for treating animals
MX2023004005A (es) Formulaciones para administración supracoroidea tales como formulaciones de gel.
CO4600644A1 (es) Vacuna contra el sindrome reproductivo y respiratorio porcino
CN120152987A (zh) 呼吸道合胞病毒rna疫苗接种
JP2020536925A5 (enExample)
ES2547855T3 (es) Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria
EP0402029A2 (en) Monoclonal antibodies for post exposure treatment of rabies
SK59393A3 (en) Use of il-4 to enhance immune response to immunogegens in vaccines
KR102675880B1 (ko) SARS-CoV-2 스파이크 단백질 및 면역글로불린의 Fc 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
Silagi et al. Relationship of antigenicity of melanoma cells grown in 5-bromodeoxyuridine to reduced tumorigenicity
CA2324477A1 (fr) Utilisation de conjugues p40 actifs par voie nasale